Cancer Research Technology, Tusk Therapeutics and University College London form pact for Immuno-oncology

Cancer Research Technology (CRT), Tusk Therapeutics and UCL (University College London) have signed a pact to research, develop and commercialise an antibody-based therapeutic against a target that is known to play a key role in immune suppression in cancer patients. Under the terms of the agreement, immuno-oncology group Tusk receives an exclusive worldwide licence from

Continue Reading